Table Info

Table 1.

Current antiviral hepatitis B virus (HBV) drugs have limitations in clinical use

Types	Names	Notes
Interferon formulations	IFN-α-1b	The effect of HBeAg seroconversion is poor [4].
Interferon formulations	PegIFN-α-2a PegIFN-α-2b	Frequent dosing is required, and influenza-like symptoms may occur [5].
Nucleos(t)ide analogs	Lamivudine	Prone to drug resistance [6]
	Adefovir	High nephrotoxicity and low genetic barrier to resistance [7]
	Telbivudine	High resistance rate [8]
	TDF	Long-term use can lead to bone loss [9].
	TAF	Different degrees of dyslipidemia may occur [10].
	ETV	Poor drug compliance [11]

IFN: interferon; HBeAg: hepatitis B e antigen; pegIFN: pegylated IFN; TDF: tenofovir disoproxil fumarate; TAF: tenofovir alafenamide fumarate; ETV: entecavir

Declarations

Author contributions

CL: Writing—review & editing, Investigation. CW: Investigation. XY: Writing—review & editing, Supervision.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Hepatitis B [Internet]. WHO; c2024 [cited 2024 Apr 28]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b

Martin P, Nguyen MH, Dieterich DT, Lau DT, Janssen HLA, Peters MG, et al. Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. Clin Gastroenterol Hepatol. 2022;20:1766–75. [DOI] [PubMed]

Sahin E, Bagci R, Bektur Aykanat NE, Kacar S, Sahinturk V. Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice. J Food Biochem. 2020;44:e13194. [DOI] [PubMed]

Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016;63:284–306. [DOI] [PubMed]

Package Insert: PEGASYS® (Peginterferon alfa-2a) [Internet]. Silver Spring, MD: U.S. Food and Drug Administration; c2002 [cited 2022 May 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf

Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B. Clin Infect Dis. 2003;36:687–96. [DOI] [PubMed]

Trepo C. A brief history of hepatitis milestones. Liver Int. 2014;34:29–37. [DOI] [PubMed]

Seto WK, Lai CL, Fung J, Wong DK, Yuen JC, Hung IF, et al. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol. 2011;55:522–8. [DOI] [PubMed]

Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al.; GS-US-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672–81. [DOI] [PubMed]

10.

Kauppinen KJ, Kivelä P, Sutinen J. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting. AIDS Patient Care STDS. 2019;33:500–6. [DOI] [PubMed]

11.

Shin JW, Jung SW, Lee SB, Lee BU, Park BR, Park EJ, et al. Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir. Am J Gastroenterol. 2018;113:998–1008. [DOI] [PubMed]

12.

Zhang Y, Li L, Qi C, Hua S, Fei X, Gong F, et al. Glycyrrhizin alleviates Con A-induced hepatitis by differentially regulating the production of IL-17 and IL-25. Biomed Pharmacother. 2019;110:692–9. [DOI] [PubMed]

13.

Shi L, Zhang S, Huang Z, Hu F, Zhang T, Wei M, et al. Baicalin promotes liver regeneration after acetaminophen-induced liver injury by inducing NLRP3 inflammasome activation. Free Radic Biol Med. 2020;160:163–77. [DOI] [PubMed]

14.

Lim SG, Baumert TF, Boni C, Gane E, Levrero M, Lok AS, et al. The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Rev Gastroenterol Hepatol. 2023;20:238–53. [DOI] [PubMed]

15.

Hu C, Song Y, Tang C, Li M, Liu J, Liu J, et al. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience. Clin Ther. 2021;43:572–81.e3. [DOI] [PubMed]

16.

European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98. [DOI] [PubMed]

17.

Zakrzewicz D, Geyer J. Multitasking Na+/Taurocholate Cotransporting Polypeptide (NTCP) as a Drug Target for HBV Infection: From Protein Engineering to Drug Discovery. Biomedicines. 2022;10:196. [DOI] [PubMed] [PMC]

18.

Guo Y, Shao J, Zhang R, Han M, Kong L, Liu Z, et al. Large HBV Surface Protein-Induced Unfolded Protein Response Dynamically Regulates p27 Degradation in Hepatocellular Carcinoma Progression. Int J Mol Sci. 2023;24:13825. [DOI] [PubMed] [PMC]

19.

Jiang Y, Han Q, Zhao H, Zhang J. The Mechanisms of HBV-Induced Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:435–50. [DOI] [PubMed] [PMC]

20.

Huang D, Wu D, Wang P, Wang Y, Yuan W, Hu D, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77:42–54. [DOI] [PubMed]

21.

Hossain MG, Ueda K. A meta-analysis on genetic variability of RT/HBsAg overlapping region of hepatitis B virus (HBV) isolates of Bangladesh. Infect Agent Cancer. 2019;14:33. [DOI] [PubMed] [PMC]

22.

Pourkarim MR, Amini-Bavil-Olyaee S, Kurbanov F, Van Ranst M, Tacke F. Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions. World J Gastroenterol. 2014;20:7152–68. [DOI] [PubMed] [PMC]

23.

Sureau C, Salisse J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology. 2013;57:985–94. [DOI] [PubMed]

24.

Hayes CN, Zhang Y, Makokha GN, Hasan MZ, Omokoko MD, Chayama K. Early events in hepatitis B virus infection: From the cell surface to the nucleus. J Gastroenterol Hepatol. 2016;31:302–9. [DOI] [PubMed]

25.

Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64:1972–84. [DOI] [PubMed]

26.

Jones SA, Hu J. Protein-primed terminal transferase activity of hepatitis B virus polymerase. J Virol. 2013;87:2563–76. [DOI] [PubMed] [PMC]

27.

Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res. 2008;134:235–49. [DOI] [PubMed]

28.

Hu J, Liu K. Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application. Viruses. 2017;9:56. [DOI] [PubMed] [PMC]

29.

Jonas MM. Hepatitis B and pregnancy: an underestimated issue. Liver Int. 2009;29:133–9. [DOI] [PubMed]

30.

Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105:94–8. [DOI] [PubMed]

31.

Yi P, Chen R, Huang Y, Zhou RR, Fan XG. Management of mother-to-child transmission of hepatitis B virus: Propositions and challenges. J Clin Virol. 2016;77:32–9. [DOI] [PubMed]

32.

Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190:489–92. [DOI] [PubMed]

33.

Nelson NP, Jamieson DJ, Murphy TV. Prevention of Perinatal Hepatitis B Virus Transmission. J Pediatric Infect Dis Soc. 2014;3:S7–12. [DOI] [PubMed] [PMC]

34.

Han GR, Xu CL, Zhao W, Yang YF. Management of chronic hepatitis B in pregnancy. World J Gastroenterol. 2012;18:4517–21. [DOI] [PubMed] [PMC]

35.

Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion. 2009;49:2454–89. [DOI] [PubMed]

36.

McCullough J, Alter HJ, Ness PM. Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy. Transfusion. 2019;59:1132–46. [DOI] [PubMed]

37.

Bremer CM, Saniewski M, Wend UC, Torres P, Lelie N, Gerlich WH, et al. Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion. 2009;49:1621–9. [DOI] [PubMed]

38.

Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol. 2003;39:S64–9. [DOI] [PubMed]

39.

Carl M, Blakey DL, Francis DP, Maynard JE. Interruption of hepatitis B transmission by modification of a gynaecologist’s surgical technique. Lancet. 1982;1:731–3. [DOI] [PubMed]

40.

Alter MJ, Margolis HS. The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am. 1990;74:1529–41. [DOI] [PubMed]

41.

Kayesh MEH, Kohara M, Tsukiyama-Kohara K. Toll-Like Receptor Response to Hepatitis B Virus Infection and Potential of TLR Agonists as Immunomodulators for Treating Chronic Hepatitis B: An Overview. Int J Mol Sci. 2021;22:10462. [DOI] [PubMed] [PMC]

42.

Gehring AJ, Protzer U. Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology. 2019;156:325–37. [DOI] [PubMed]

43.

Wang Q, Pan W, Liu Y, Luo J, Zhu D, Lu Y, et al. Hepatitis B Virus-Specific CD8+ T Cells Maintain Functional Exhaustion after Antigen Reexposure in an Acute Activation Immune Environment. Front Immunol. 2018;9:219. [DOI] [PubMed] [PMC]

44.

Lim CJ, Lee YH, Pan L, Lai L, Chua C, Wasser M, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68:916–27. [DOI] [PubMed]

45.

Chen Y, Tian Z. HBV-Induced Immune Imbalance in the Development of HCC. Front Immunol. 2019;10:2048. [DOI] [PubMed] [PMC]

46.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4. [DOI] [PubMed]

47.

Zhang HH, Mei MH, Fei R, Liu F, Wang JH, Liao WJ, et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J Viral Hepat. 2010;17:34–43. [DOI] [PubMed]

48.

Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, et al. TGF-β-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma. Cancer Cell. 2012;22:291–303. [DOI] [PubMed] [PMC]

49.

Yang J, Li L. CD4⁺CD25⁺ regulatory T-cells: a potential target for treating patients with chronic HBV infection. Cell Mol Immunol. 2017;14:800–1. [DOI] [PubMed] [PMC]

50.

Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018;128:4588–603. [DOI] [PubMed] [PMC]

51.

Peng H, Sun R. Liver-resident NK cells and their potential functions. Cell Mol Immunol. 2017;14:890–4. [DOI] [PubMed] [PMC]

52.

Li H, Zhai N, Wang Z, Song H, Yang Y, Cui A, et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection. Gut. 2018;67:2035–44. [DOI] [PubMed] [PMC]

53.

Yang Y, Han Q, Hou Z, Zhang C, Tian Z, Zhang J. Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cell Mol Immunol. 2017;14:465–75. [DOI] [PubMed] [PMC]

54.

Zhang QF, Yin WW, Xia Y, Yi YY, He QF, Wang X, et al. Liver-infiltrating CD11b^–CD27^– NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. Cell Mol Immunol. 2017;14:819–29. [DOI] [PubMed] [PMC]

55.

Chen Y, Hao X, Sun R, Wei H, Tian Z. Natural Killer Cell-Derived Interferon-Gamma Promotes Hepatocellular Carcinoma Through the Epithelial Cell Adhesion Molecule-Epithelial-to-Mesenchymal Transition Axis in Hepatitis B Virus Transgenic Mice. Hepatology. 2019;69:1735–50. [DOI] [PubMed]

56.

Kong X, Sun R, Chen Y, Wei H, Tian Z. γδT cells Drive Myeloid-Derived Suppressor Cell-Mediated CD8+ T cell Exhaustion in Hepatitis B Virus-Induced Immunotolerance. J Immunol. 2014;193:1645–53. [DOI] [PubMed]

57.

Chang KM, Traum D, Park JJ, Ho S, Ojiro K, Wong DK, et al. Distinct phenotype and function of circulating Vδ1⁺ and Vδ2⁺γδT cells in acute and chronic hepatitis B. PLoS Pathog. 2019;15:e1007715. [DOI] [PubMed] [PMC]

58.

Deng Y, Zhao H, Zhou J, Yan L, Wang G; China HepB-Related Fibrosis Assessment Research Group. Complement 5a is an indicator of significant fibrosis and earlier cirrhosis in patients chronically infected with hepatitis B virus. Infection. 2017;45:75–81. [DOI] [PubMed] [PMC]

59.

Luo J, Chen S, Wang J, Ou S, Zhang W, Liu Y, et al. Genetic polymorphisms in complement receptor 1 gene and its association with HBV-related liver disease: A case-control study. Gene. 2019;688:107–18. [DOI] [PubMed]

60.

Lee HW, Lee JS, Ahn SH. Hepatitis B Virus Cure: Targets and Future Therapies. Int J Mol Sci. 2020;22:213. [DOI] [PubMed] [PMC]

61.

Cargill T, Barnes E. Therapeutic vaccination for treatment of chronic hepatitis B. Clin Exp Immunol. 2021;205:106–18. [DOI] [PubMed] [PMC]

62.

Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18:827–44. [DOI] [PubMed]

63.

Wang W, Zhou X, Bian Y, Wang S, Chai Q, Guo Z, et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat Nanotechnol. 2020;15:406–16. [DOI] [PubMed] [PMC]

64.

Zhao F, Xie X, Tan X, Yu H, Tian M, Lv H, et al. The Functions of Hepatitis B Virus Encoding Proteins: Viral Persistence and Liver Pathogenesis. Front Immunol. 2021;12:691766. [DOI] [PubMed] [PMC]

65.

Schumann A, Fiedler M, Dahmen U, Grosse-Wilde H, Roggendorf M, Lindemann M. Cellular and humoral immune response to a third generation hepatitis B vaccine. J Viral Hepat. 2007;14:592–8. [DOI] [PubMed]

66.

Yu X, Zheng Y, Zeng D, Zhou Y, Sun J, Su M, et al. Decreased frequency of a novel T-lymphocyte subset, CD3⁺ CD4^– CD7⁺ CD57^– T cells, in hepatitis B virus-related end-stage liver disease might contribute to disease progression. J Med Virol. 2023;95:e28129. [DOI] [PubMed]

67.

Whitacre DC, Peters CJ, Sureau C, Nio K, Li F, Su L, et al. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance. Hum Vaccin Immunother. 2020;16:251–68. [DOI] [PubMed] [PMC]

68.

Tzeng TT, Chai KM, Shen KY, Yu CY, Yang SJ, Huang WC, et al. A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection. NPJ Vaccines. 2022;7:60. [DOI] [PubMed] [PMC]

69.

Su J, Brunner L, Ates Oz E, Sacherl J, Frank G, Kerth HA, et al. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models. J Hepatol. 2023;78:717–30. [DOI] [PubMed]

70.

Wang Y, Wu S, Wang ZC, Zhu XM, Yin XT, Gao K, et al. Enhanced immunity and antiviral effects of an HBV-DNA vaccine delivered by a DC-targeting protein. J Viral Hepat. 2016;23:798–804. [DOI] [PubMed]

71.

Greber UF, Flatt JW. Adenovirus Entry: From Infection to Immunity. Annu Rev Virol. 2019;6:177–97. [DOI] [PubMed]

72.

Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, et al. Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Hum Vaccin Immunother. 2020;16:388–99. [DOI] [PubMed] [PMC]

73.

Li P, Feng F, Pan E, Fan X, Yang Q, Guan M, et al. Scavenger receptor-mediated Ad5 entry and acLDL accumulation in monocytes/macrophages synergistically trigger innate responses against viral infection. Virology. 2018;519:86–98. [DOI] [PubMed]

74.

Cargill T, Cicconi P, Brown A, Holland L, Karanth B, Rutkowski K, et al. HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV. JHEP Rep. 2023;5:100885. [DOI] [PubMed] [PMC]

75.

Zhang M, Yuan Y, Mao P, Zhuang Y. Analysis on morbidity and mortality of viral hepatitis in China, 2004-2013. Zhonghua Liu Xing Bing Xue Za Zhi. 2015;36:144–7. Chinese. [PubMed]

76.

Hu R, Cao W, Zhang X. Cost-effectiveness analysis of hepatitis B vaccination in People’s Liberation Army. Zhonghua Liu Xing Bing Xue Za Zhi. 2001;2:142–5. Chinese. [PubMed]

77.

Zhu D, Wang J, Wangen KR. Hepatitis B vaccination coverage rates among adults in rural China: Are economic barriers relevant? Vaccine. 2014;32:6705–10. [DOI] [PubMed]

78.

Zhu D, Guo N, Wang J, Nicholas S, Wang Z, Zhang G, et al. Socioeconomic inequality in Hepatitis B vaccination of rural adults in China. Hum Vaccin Immunother. 2018;14:464–70. [DOI] [PubMed] [PMC]